Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor treatment. It is important to identify and manage it promptly. We present two cases of immune-related de novo myasthenia gravis observed at the Modena Cancer Center in two elderly patients treated with two anti-PD-1 monoclonal antibodies: cemiplimab and nivolumab.
JeyakumarNEtchegarayMHenryJ, et al. The terrible triad of checkpoint inhibition: a case report of myasthenia gravis, myocarditis, and myositis induced by cemiplimab in a patient with metastatic cutaneous squamous cell carcinoma. Case Reports Immunol2020; 2020: 5126717.
2.
CuzzubboSJaveriFTissierM, et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur J Cancer2017; 73: 1–8.
3.
ShiJNiuJShenD, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. Thorac Cancer2020; 11: 481–487.
4.
SpainLWallsGJulveM, et al. Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature. Ann Oncol2017; 28: 377–385.
5.
ZimmerLGoldingerSMHofmannL, et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer2016; 60: 210–225.
6.
MakariousDHorwoodKCowardJIG. Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors. Eur J Cancer2017; 82: 128–136.
7.
SafaHJohnsonDHTrinhVA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer2019; 7: 319.
8.
YuenCFlemingGMeyersM, et al. Myasthenia gravis induced by avelumab. Immunotherapy2019; 11: 1181–1185.
9.
BrahmerJRLacchettiCSchneiderBJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol2018; 36: 1714–1768.
10.
MillerRGMilner-BrownHSMirkaA.Prednisone-induced worsening of neuromuscular function in myasthenia gravis. Neurology1986; 36: 729–732.
